PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 12, Pages 2938
Publisher
MDPI AG
Online
2021-06-12
DOI
10.3390/cancers13122938
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
- (2021) Tadashi Watabe et al. ANNALS OF NUCLEAR MEDICINE
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
- (2021) Francesco Ceci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
- (2021) Reyhaneh Manafi-Farid et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Prostate-specific Membrane Antigen PET in Prostate Cancer
- (2021) Courtney Lawhn-Heath et al. RADIOLOGY
- Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
- (2021) Sangwon Han et al. Diagnostics
- Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
- (2020) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: a Single-Center Retrospective Study
- (2020) Thorsten Derlin et al. JOURNAL OF NUCLEAR MEDICINE
- Influence of short‐term dexamethasone on the efficacy of 177 Lu‐PSMA‐617 in patients with metastatic castration‐resistant prostate cancer
- (2020) Thorsten Derlin et al. PROSTATE
- Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
- (2020) Moran Gadot et al. Cancers
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
- (2020) Robert Seifert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
- (2020) Kerstin Michalski et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
- (2019) Wolfgang P. Fendler et al. JAMA Oncology
- Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy
- (2019) Lino M. Sawicki et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- (2019) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Is the “VISION” of Radioligand Therapy for Prostate Cancer becoming reality? An Overview of the Phase III trial and the Importance for the Future of Theranostics
- (2019) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
- (2019) Hendrik Rathke et al. JOURNAL OF NUCLEAR MEDICINE
- Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy
- (2019) Kerstin Michalski et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
- (2019) Madhav Prasad Yadav et al. CLINICAL NUCLEAR MEDICINE
- PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies
- (2018) Steven P. Rowe et al. EUROPEAN UROLOGY
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
- (2018) Yong Joong Kim et al. CLINICAL NUCLEAR MEDICINE
- Genetics and biology of prostate cancer
- (2018) Guocan Wang et al. GENES & DEVELOPMENT
- Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy
- (2018) Frederik L. Giesel et al. JOURNAL OF NUCLEAR MEDICINE
- Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases
- (2018) Paola M. Perez et al. CLINICAL NUCLEAR MEDICINE
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Initial Experience with Volumetric68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
- (2017) Sebastian Schmuck et al. JOURNAL OF NUCLEAR MEDICINE
- Intraindividual Comparison of18F-PSMA-1007 and18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
- (2017) Frederik L. Giesel et al. JOURNAL OF NUCLEAR MEDICINE
- Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
- (2017) David LH Chan et al. Theranostics
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
- (2016) Steven P. Rowe et al. MOLECULAR IMAGING AND BIOLOGY
- A Systematic Review of the Factors Affecting Accuracy of SUV Measurements
- (2010) Michael C. Adams et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Methods and Limitations of Assessing New Noninvasive Tests
- (2008) Rory Hachamovitch et al. CIRCULATION
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now